Internal Control · 2025
In this section9 topics
- Internal Control — Board Opinion1 item
- Adequacy & Appropriateness of the Internal Control System1 item
- Internal Control Deficiencies1 item
- Audit Committee & Auditor Observations2 items
- Opinion on the Head of Internal Audit2 items
- Appointment, Discharge & Transfer of the Head of Internal Audit2 items
- Related Party Transactions1 item
- Counterparties & Transactions3 items
- Policy & Future Trends1 item
Internal Control — Board Opinion
Summary of the Board's Opinion on Internal Control
The Company and its subsidiaries (“ The Group ”) recognizes the importance of having a good internal control system to ensure that the Group has appropriate and sufficient internal control systems in accordance with good corporate governance principles for overseeing business operations, as well as to prevent risks and damages that may occur to the Group and its stakeholders, and to prepare and disclose complete, accurate, and reliable financial reports.
The Board of Directors of Genesis Fertility Center Public Company Limited has emphasized the importance of the Company establishing a good and effective internal control system, clearly stating this matter in the corporate governance policy of
the Company, believing that a good internal control system will help reduce risks and prevent damages from the Company's business operations and enable the Company to achieve its Vision, Mission, and goals. Therefore, the Audit Committee has been assigned the authority, duties, and responsibilities to review that the Company has appropriate and effective Internal Control and Internal Audit systems. The Audit Committee has reported that the Company has appropriate internal control and internal audit systems, meaning that the assessment of the adequacy of the Company's internal control system has been developed from the international internal control framework of COSO 2013 (The Committee of Sponsoring Organizations of The Treadway Commission).
From the self-assessment of the Audit Committee's performance for the year 2025, the Audit Committee has performed its duties and responsibilities as stipulated in its charter, utilizing its knowledge, capabilities, diligence, prudence, and sufficient independence. It has also provided effective opinions and recommendations, complied fully and correctly with laws, Stock Exchange regulations, and relevant laws, and continuously developed to support the company's sustainable corporate governance.
Adequacy & Appropriateness of the Internal Control System
Internal Control Framework Used
| Framework | Detail | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The Committee of Sponsoring Organizations of the Treadway Commission (COSO) | Internal Control Genesis Fertility Center Public Company Limited places importance on internal control in accordance with international standards. Based on the assessment of the internal control system following the guidelines of The Committee of Sponsoring Organizations of Treadway Commission ("COSO"), which consists of the following five components:
At the 10/2025 Board of Directors' Meeting on December 15, 2025, the Board considered the adequacy of the internal control system based on the assessment form of the Securities and Exchange Commission (SEC), as evaluated by the Internal Audit Department, reported to the executive management, and reviewed by the Audit Committee. The Board of Directors concluded that the company's internal control system is adequate and appropriate. The company ensures sufficient personnel for efficient operation of the internal control system, which also includes an internal control system capable of monitoring and overseeing. Furthermore, the company has established an independent internal audit function to monitor and evaluate internal controls by engaging an external internal auditor (Outsource) to audit the internal control system. This auditor reports directly to the Audit Committee, which has reviewed and approved the company's internal control system adequacy assessment form for 2025. Internal Control System Adequacy Assessment Form, Year 2025
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Internal Control Deficiencies
Number of Deficiencies
| Metric | Current Year | Previous Year | Two Years Ago |
|---|---|---|---|
| Total number of internal control system deficiencies (cases) | 0 | 0 | 0 |
Audit Committee & Auditor Observations
Audit Committee's Opinion Differs from the Board's
No
Auditor Has Observations on Internal Control
No
Opinion on the Head of Internal Audit
Head of Internal Audit
3160
Audit Committee's Opinion on the Head of Internal Audit
The company's Internal Audit Department is independent of management and reports directly to the Audit Committee, which oversees that internal audit operations are conducted independently, impartially, and in accordance with professional internal auditing standards. For general administration and budget matters of the internal audit unit, it reports to the Chief Executive Officer.
The Internal Audit Department plays a role in providing Assurance Services and Consulting Services, focusing on evaluating the adequacy and effectiveness of the company's internal control systems, risk management, and corporate governance processes. This is to support the company's operations in being efficient, transparent, and capable of achieving its defined business objectives. Such operations adhere to the internal control framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
The annual internal audit plan must be considered by the Audit Committee, utilizing a Risk-Based Audit Approach to cover the company's critical operational processes, as well as to support the continuous monitoring and improvement of internal control systems, risk management, and corporate governance for ongoing effectiveness.
The Head of Internal Audit of the company is Mr. Karan Peeraboon of P.P. Internal Audit Co., Ltd. The Audit Committee is of the opinion that the qualifications of the Head of Internal Audit are appropriate and that the duties are performed effectively.
The Head of Internal Audit of the company has the following duties and responsibilities:
Prepare an internal audit plan for submission to the Audit Committee for approval.
Review the appropriateness of asset safeguarding, including testing for the existence of assets and their efficient and effective utilization.
Review and report on the reliability and completeness of financial information, including operational processes for evaluation and measurement.
Review work systems that may have a significant impact on operations and reporting to ensure compliance with the organization's policies, plans, and procedures, as well as all relevant laws.
Review the adequacy and appropriateness of the organization's internal control systems to develop and improve them for greater efficiency and suitability.
Review and support the continuous and consistent development of work systems for increased efficiency.
Perform other internal audit-related duties as assigned by the Audit Committee or management.
(7.1) Report audit results, including progress of operations against the planned schedule.
(7.2) Support operations and provide necessary information for the operations of the Audit Committee and related management.
Audit Work
(7.3) Develop audit personnel to possess sufficient professional and business knowledge and expertise.
(7.4) Perform other assigned duties.
Appointment, Discharge & Transfer of the Head of Internal Audit
Requires Audit Committee Approval
Yes
Description
The appointment, removal, transfer, or termination of employment of the Head of the Internal Audit Unit, and the performance evaluation of personnel of the Internal Audit Unit, must be approved by the Audit Committee.
Related Party Transactions
Has Related Party Transactions
Yes
Counterparties & Transactions
Monetary Unit
1
Counterparties with Potential Conflicts
| Name | Person / Juristic Person | Type of Business | Nature of Relationship | As of Date (YYYY-MM-DD) |
|---|---|---|---|---|
| Genosomics Company Limited | Juristic Person | Provide genetic material and chromosomal integrity analysis services using Next Generation Sequencing (NGS). | Subsidiary (99.99% owned) | 2025-12-31T00:00 |
| GFC Fertility Group Company Limited | Juristic Person | Holding company for expanding investments in other businesses with the objective of conducting other business activities that generate benefits or support the company's operations. | Subsidiary company (99.99% shareholding) | 2025-12-31T00:00 |
| GFC Ubon Company Limited | Juristic Person | Operates a medical and surgical office, offering treatment and consultation for individuals experiencing infertility, and treating general or specific diseases. | Subsidiary (company holds 60.00% of shares) | 2025-12-31T00:00 |
| Mr. Pitak Laohakiat | Person | Serves as a part-time physician / major shareholder (25.76%) / Chairman of the Board / Chief Executive Officer of Genesis Fertility Center Public Company Limited / Director of Genosomics Co., Ltd., GFC Fertility Group Co., Ltd., and GFC Ubon Co., Ltd. | 2025-12-31T00:00 | |
| Mr. Pramook Wongthanakiati | Person | Holds 18.77% of shares / Vice Chairman of the Board / Chairman of the Nomination and Remuneration Committee / Executive Director of Genesis Fertility Center Public Company Limited / Director of Genosomics Co., Ltd., GFC Fertility Group Co., Ltd., GFC Ubon Co., Ltd. | 2025-12-31T00:00 | |
| Ms. Pasiree Orawattanasrikul | Person | Is a shareholder with 9.12% / Executive Director of Genesis Fertility Center Public Company Limited / Director of Genosomics Co., Ltd., GFC Fertility Group Co., Ltd. (Resigned from the Board of Directors and the Corporate Governance and Social Responsibility Committee on August 11, 2025) | 2025-12-31T00:00 | |
| Ms. Piyada Wiratpong | Person | Chief Laboratory Officer / Embryologist Assistant Specialist / Holds 7.43% of shares / Director / Risk Management Committee Member / Executive Director of Genesis Fertility Center Public Company Limited / Director of Genosomics Co., Ltd., GFC Fertility Group Co., Ltd., GFC Ubon Co., Ltd. | 2025-12-31T00:00 | |
| Ms. Parawan Tangtham | Person | Medical Director / Attending Physician / Shareholder (7.51%) / Company Director / Risk Management Committee Member / Executive Director of Genesis Fertility Center Public Company Limited / Director of Genosomics Co., Ltd., GFC Fertility Group Co., Ltd. | 2025-12-31T00:00 | |
| Mr. Ek Pattaratanakul | Person | Holds 0.15% of shares / Company Director / Director of Corporate Governance and Social Responsibility (Resigned from the positions of Company Director and Director of Corporate Governance and Social Responsibility on December 16) | 2025-12-31T00:00 | |
| Mr. Korapat Atchariyamanikun | Person | Director of Genesis Fertility Center Public Company Limited / Holds 1.07% of shares (Resigned from the positions of Chief Executive Officer and Executive Director of Genesis Fertility Center Public Company Limited on July 14, 2025, and was appointed as a Company Director on August 12, 2025) | 2025-12-31T00:00 | |
| Ms. Thitima Chaisrisawatsuk | Person | Shareholder, Director, Managing Director, and Company Physician, GFC Ubon Co., Ltd. / holds 0.04% of shares. | 2025-12-31T00:00 | |
| Mr. Rojjanin Luangpipatsorn | Person | Shareholders and Directors of GFC Ubon Co., Ltd. | 2025-12-31T00:00 | |
| Ms. Sudarat Chaisrisawatsuk | Person | Persons related to the directors and shareholders of the subsidiary / holding 0.01% of shares | 2025-12-31T00:00 | |
| Ms.Thitima Chaisrisawasuksuk and Mr. Rojanin Lueangphipatthanason | Person |
| 2025-12-31T00:00 |
Transactions by Counterparty
| Transactions |
|---|
| 8926520.0 · Necessity: The company paid professional fees to Assoc. Prof. Dr. Pitak Laohakiat as a Part-Time physician. The policy and method for determining such professional fee rates are approved by the company's professional fee structure policy, which categorizes fees by service provided. These rates are referenced against professional fees based on the physician's experience from other medical facilities, the complexity of the treatment, costs associated with the service items, and gross profit margin, among other factors. · Description: The determination of professional fees for each service (Package) of the company will be a joint consideration among physicians, management, and the marketing department. The professional fees paid by the company to Assoc. Prof. Dr. Pitak Laohgergkiat are higher than those paid to other physicians. This is because Assoc. Prof. Dr. Pitak Laohgergkiat provides treatment under Package 3, which is a treatment package provided by physicians with over 10 years of expertise and experience. However, the conditions for paying professional fees to Assoc. Prof. Dr. Pitak Laohgergkiat remain the same as those paid to other physicians. · As of yesteryear: 11896355.0 · Nature of transaction: Professional fees · Audit committee opinion: The Audit Committee considered and was of the opinion that the aforementioned transaction was relatively difficult to assess due to the premium nature of the Group's services. It was therefore challenging to determine the fair value or market price. Nevertheless, the Audit Committee considered the fairness and substance of the transaction (assessing prices or conditions as normal). It was considered that the added profit margin must be based on the same policy applied to other medical professionals. The Audit Committee is confident that the company continues to operate under normal conditions. · As of year before yesteryear: 18185535.0 |
| 1996000.0 · Necessity: The company has paid professional fees for medical technology to Ms. Piyada Wiratpong as a full-time Embryologist. The policy and method for determining the payment rate of these professional fees have been approved by the company in accordance with its professional fee structure policy, which is categorized by service. This structure references professional fees based on the experience of medical technologists from other medical facilities, the complexity of treatment, costs associated with the service items, and gross profit margin, among other factors. · Description: The company has paid professional fees for medical technology to Ms. Piyada Wiratpong as a full-time Embryologist. The policy and method for determining the payment rate of these professional fees have been approved by the company in accordance with its professional fee structure policy, which is categorized by service. This structure references professional fees based on the experience of medical technologists from other medical facilities, the complexity of treatment, costs associated with the service items, and gross profit margin, among other factors. · As of yesteryear: 4388000.0 · Nature of transaction: Professional fees · Audit committee opinion: The Audit Committee considered and was of the opinion that the aforementioned transaction was relatively difficult to assess due to the premium nature of the Group's services, making it difficult to determine the fair value or market price. Nevertheless, the Audit Committee considered the fairness and substance of the transaction (considering normal prices or conditions). It considered that the added profit margin must be based on the same policy applied to other medical technologists. The Audit Committee is confident that the company continues to operate under normal conditions. · As of year before yesteryear: 6031000.0 |
| 6990730.0 · Necessity: The Company has paid professional fees to Dr. Parawan Tangtham as a full-time physician. The policy and method for determining the rate of such professional fees have been approved by the Company in accordance with its professional fee structure policy. This structure is categorized by the services provided and is based on professional fees from the experience of physicians at other medical facilities, the complexity of treatment, costs associated with the service items, and gross profit margin, among other factors. · Description: The company's determination of professional service fees for each service (Package) will be a joint consideration among physicians, management, and the marketing department. The price and conditions for paying professional fees to Dr. Parawan Tangtham are the same as those paid to other physicians. · As of yesteryear: 9603815.0 · Nature of transaction: Professional fees · Audit committee opinion: The Audit Committee considered and was of the opinion that the aforementioned transaction was relatively difficult to assess due to the premium nature of the Group's services. It was therefore challenging to determine the fair value or market price. Nevertheless, the Audit Committee considered the fairness and substance of the transaction (assessing prices or conditions as normal). It was considered that the added profit margin must be based on the same policy applied to other medical professionals. The Audit Committee is confident that the company continues to operate under normal conditions. · As of year before yesteryear: 9975330.0 |
| 6793184.0 · Necessity: The Company has paid professional fees to Dr. Thitima Chaisrisawatsuk as a full-time physician. The policy and method for determining such professional fee rates have been approved by the Company in accordance with its professional fee structure policy, which is categorized by service. This is referenced from the professional fees of Genesis Fertility Center Public Company Limited (the parent company), the experience of physicians from other medical facilities, the complexity of treatment, costs related to service items, and gross profit margin, among others. · Description: The company's determination of professional service fees for each service package will be a joint consideration among physicians, management, and the marketing department. The price and conditions for paying professional fees to Dr. Thitima Chaisrisawatsuk are the same as those paid to other physicians. · As of yesteryear: 1700085.0 · Nature of transaction: Professional fees · Audit committee opinion: The Audit Committee considered and was of the opinion that the aforementioned transaction was relatively difficult to assess due to the premium nature of the Group's services. It was therefore challenging to determine the fair value or market price. Nevertheless, the Audit Committee considered the fairness and substance of the transaction (assessing prices or conditions as normal). It was considered that the added profit margin must be based on the same policy applied to other medical professionals. The Audit Committee is confident that the company continues to operate under normal conditions. · As of year before yesteryear: 0.0 |
| 17376676.01 · Necessity: The Company has entered into a building lease agreement with Mr. Rojanin Lueangphatthanason and Ms. Thitima Chaisrisawasuksuk for use in its business operations. The rental rate is mutually agreed and is comparable to market rates, with an increase of 5% every three years. · Description: GFC Ubon Co., Ltd. (a subsidiary) has entered into two building lease agreements with Mr. Rojanin Lueangphatthanason and Ms. Thitima Chaisrisawasuksuk (the lessors), as follows: • Lease Agreement No. 1, dated 15 August 2024, with a lease term of 3 years. The lessors have granted the lessee the right to extend the lease for an additional 7 years, resulting in a total lease term (including the extension option) of 10 years, expiring on 14 August 2034. • Lease Agreement No. 2, dated 15 September 2025, with a lease term of 3 years. The lessors have granted the lessee the right to extend the lease for an additional 6 years, resulting in a total lease term (including the extension option) of 9 years, expiring on 14 August 2034. As both lease agreements provide reasonable certainty that the extension options will be exercised, the subsidiary has determined the lease term based on the contractual lease period including the extension options. The rental rates are mutually agreed and comparable to market rates, with an increase of 5% every three years. · As of yesteryear: 15922898.08 · Nature of transaction: Interest expense from lease liabilities · Audit committee opinion: The Audit Committee has considered and is of the opinion that the transaction is in the normal course of business and is reasonable. · As of year before yesteryear: 0.0 |
Policy & Future Trends
Policy, Measures & Approval Process
Policy on Connected Transactions
-
Directors and executives of the company shall prepare a report on their interests or those of related persons and inform the company, so that the company has information for internal use in complying with the requirements regarding connected transactions.
-
Avoid connected transactions that may lead to conflicts of interest.
-
In cases where connected transactions are necessary, all connected transactions of the company must be presented to and approved by the management, the Board of Directors, or the shareholders' meeting (as the case may be).
-
Follow the company's operating procedures for connected transactions and comply with the criteria set by the Capital Market Supervisory Board, the Securities and Exchange Commission, and the Stock Exchange.
-
Determine prices and conditions for connected transactions as if dealing with external parties (Arm's length basis), which must be fair and reasonable, by comparing prices of goods or services with external prices under similar conditions.
-
In considering connected transactions, the company may appoint an independent appraiser to evaluate and compare prices for significant connected transactions, to ensure that such connected transactions are reasonable and for the company's best interest.
Company's procedures for connected transactions
|
Types of Connected Transactions |
Value of the transaction |
Company's operations |
|||
|
Can proceed immediately |
Disclose to the Stock Exchange of Thailand |
Request approval Board of Directors |
Request meeting approval Shareholders |
||
|
1. Ordinary business transactions or ordinary business support transactions |
|||||
|
1.1 Ordinary business transactions with general commercial terms. |
Unlimited value of transactions |
|
|||
|
1.2 Ordinary business support transactions with general commercial terms and where compensation can be calculated from assets or reference values. |
Unlimited value of transactions |
|
|||
|
1.3 Ordinary business support transactions with general commercial terms and where compensation cannot be calculated from assets or reference values. |
Small |
|
|||
|
Medium |
|
|
|||
|
Large |
|
|
|||
|
1.4 Ordinary business transactions or ordinary business support transactions without general commercial terms. |
Small |
|
|||
|
Medium |
|
|
|||
|
Large |
|
|
|
||
|
2. Lease or sublease of real estate for not more than 3 years and cannot be shown to have general commercial terms. |
Small |
|
|||
|
Medium |
|
|
|||
|
Large |
|
|
|||
|
3. Transactions related to assets or services |
Small |
|
|||
|
Medium |
|
|
|||
|
Large |
|
|
|
||
|
4. Financial assistance transactions (giving or receiving) |
|||||
|
4.1 The company or its subsidiaries provide financial assistance to the following connected persons:
|
< 100 million Baht or < 3% of net tangible assets, whichever is lower |
|
|
||
|
< 100 million Baht or < 3% of net tangible assets, whichever is lower |
|
|
|
||
|
4.2 Other financial assistance transactions (giving or receiving) apart from 4.1 |
Small |
|
|||
|
Medium |
|
|
|||
|
Large |
|
|
|
||
Note:
-
Transaction value :
Small transactions are those with a value less than or equal to 1 million Baht or less than or equal to 0.03% of net tangible assets, whichever is higher.
Medium transactions are those with a value greater than 1 million Baht but less than 20 million Baht, or greater than 0.03% but less than 3% of net tangible assets, whichever is higher.
Large transactions are those with a value greater than or equal to 20 million Baht or greater than 3% of net tangible assets, whichever is higher.
Net tangible assets Means total assets less intangible assets such as goodwill, deferred expenses, and less liabilities and shareholders' equity.
Minority
Net tangible asset value Means the book value of the net tangible assets of the company and its subsidiaries as disclosed in the financial statements, as the case may be.
Financial statements Means the latest consolidated financial statements of the company that have been audited or reviewed by an auditor.
-
In cases where the company or its subsidiaries and connected persons jointly provide financial assistance to a juristic person in which the company or its subsidiaries and connected persons are shareholders, in proportion to their interest in that juristic person, under general commercial terms or better, the company shall be exempt from seeking approval from the shareholders' meeting for such transactions.

